back to overview


First Closing and first investment accomplished

May 01, 2016 + Jessica Di Palo
5 Min read

MTIP reaches important milestones

MTIP Fund 1 firstclosing

The investment fund launched by MedTech Innovation Partners AG (MTIP) at the beginning of 2016 made a first closing of CHF 30 million in April. In May 2016, the first investment in ReActive Robotics GmbH was made.

Basel, May 2016: MITP’s first fund which was launched six months ago reached a first close of CHF 30 million in April 2016. The capital was raised by ten different investors including pension funds, family offices, hospitals, foundations. “First-time closing is an enormously important milestone in our industry, one that is difficult to achieve. We are therefore particularly pleased that MTIP has successfully reached its first closing,” emphasises Dr. Christoph Kausch, CEO of MTIP. The target volume of this fund is CHF 40 million. All investments in the fund will be in the same share class and same conditions will apply.

Just as pleasing as the first closing was the first investment MTIP made in May 2016. As the lead investor in ReActive Robotics GmbH, MTIP promotes a company that facilitates the accelerated and improved recovery of patients with the aid of robotic technology. Germany’s largest venture capital fund, the High-Tech Gründerfond, co-invested. Contact with the company had been established via MTIP’s high-caliber advisory board and the associated affiliation to robotics research at the ETH. ReActive Robotics develops adaptive and intelligent therapy robotics which automate Early Mobilization in the intensive care unit. Using robotic modules, which can be attached to the patient bed as required, patients can be mobilised directly in their hospital bed. Thus, in contrast to existing solutions, the time-intensive and often dangerous transfer of intensive care patients onto a separate therapy device is no longer required. The potential market size is estimated to exceed € 2 billion. The device will be launched in Europe in early 2018. “We are delighted to be investing into a business model that offers benefits for patients, the health care system and investors alike,” says Dr. Christoph Kausch. He and his team are already evaluating other attractive startup investments which, in view of the promising investment pipeline, will no doubt follow.

Share the Article


Dealroom Report: Tooling the Physicians of the Future

European startups addressing clinical capacity bottlenecks


MTIP Office Featured in Swiss Office Blog

MTIP Office Featured in Swiss Office Blog


Diversity, Equity, and Inclusion: The 3 Key Drivers for Success

We have talked with Caroline Noublanche, CEO of our portfolio company Apricity, about her company’s DEI efforts.


Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch

Growth Capital Decisions


Rahel Hafner Receives Certificate in ESG Investing by CFA Institute

Rahel Hafner Receives Certificate in ESG Investing


What Makes a Great Founder/Investor Relationship?

Interview with the CEO and Co-Founder Kai Eberhardt of our portfolio company Oviva


MTIP’s HealthCare Clinic 2022

This year's HealthCare Clinic was held under the motto: "Surfing the Healthtech Waves of Change".


Christoph Kausch selected by Real Deals as most influential for 2022

Christoph Kausch named by Real Deals most influential for 2022


MTIP leads €17 million financing round in virtual fertility clinic Apricity

New MTIP investment


MTIP leads the €20 million growth financing round in LynxCare

Largest capital round ever in digital health in Belgium


Pioneering the use of machine learning algorithms to turbo-charge drug development

Intelligencia revolutionizes drug development


The psychology of decision making

What makes a good investor?


Revolutionizing medical triage with artificial intelligence

Mediktor's solution for medical triage


MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments

MTIP Fund II is closed!


Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics

Cynerio's new product Cynerio Now!


MTIP invests in Mediktor

New investment in Mediktor


SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right


MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round


MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia


Private Equity 101: Part one – Glossary

Are you new to the healthtech space?


Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey


Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations


MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II